While the future of Celgene (CELG +0.00%) looks bright in terms of the company's promising pipeline, its present is facing some serious threats. In this video, Fool health-care analyst David Williamson tells investors how the company's present success is absolutely tied to its two key drugs, Revlimid and Vidaza. David highlights the threats to these drugs both in the form of generics, as well as very fierce competition.
2 Big Risks Threatening Celgene
By Dave Williamson – Mar 25, 2013 at 7:15PM
NASDAQ: CELG
Celgene
2 big risks every Celgene investor needs to be aware of.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid